Saloni Arya

Good afternoon . So Mr. Shiva, most of the big picture and broader questions have already been asked by Saket ji. I'll just get to the specific segments and sp ecific developments. So I'll start with the Track & Trace division first. In the earlier calls and presentations, we have been updating that, we've been in negotiations with two of the large pharma companies, and it was at the final stage.

You said ₹20 crore s in this quarter we have done. Last year, I'm assuming we didn't do any…

₹20 crores in the last financial year. Okay. What about this quarter?